Lilly sues two medical spas over copycat weight-loss drugs
Portfolio Pulse from
Eli Lilly has filed lawsuits against two medical spas for selling unapproved products that claim to contain tirzepatide, the main ingredient in its weight-loss drug Zepbound.
January 13, 2025 | 10:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eli Lilly is taking legal action against two medical spas for selling unapproved products with tirzepatide, impacting its weight-loss drug Zepbound.
The lawsuit aims to protect Eli Lilly's market for Zepbound by targeting unauthorized sellers of products claiming to contain its key ingredient, potentially safeguarding its revenue and market share.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90